Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSF1 | Q00613 | 7/20 | 0.60 |
| ▸ | PIR | O00625 | 4/20 | 0.60 |
| ▸ | BRAF | P15056 | 2/20 | 0.60 |
| ▸ | GSK3B | P49841 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | BMX | P51813 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16621185 | 0.89 | HSF1 (0.61) | HSF1PIRBRAFGSK3BNPC1 | |
| SCHEMBL18109868 | 0.86 | HSF1 (0.65) | HSF1PIRBRAFGSK3BHPGD | |
| SCHEMBL16620890 | 0.81 | HSF1 (0.59) | HSF1PIRBRAFGSK3BNPC1 | |
| SCHEMBL18109855 | 0.81 | HSF1 (0.61) | HSF1PIRBRAFGSK3BNPC1 | |
| SCHEMBL16621079 | 0.79 | HSF1 (0.57) | HSF1PIRBRAFGSK3BNPC1 | |
| SCHEMBL16621314 | 0.78 | HSF1 (0.81) | HSF1PIRBRAFGSK3BHPGD | |
| SCHEMBL16621147 | 0.77 | HSF1 (0.73) | HSF1PIRBRAFGSK3BHPGD | |
| SCHEMBL18109848 | 0.77 | HSF1 (0.76) | HSF1PIRBRAFGSK3BNPC1 | |
| SCHEMBL16621452 | 0.77 | HSF1 (0.76) | HSF1PIRBRAFGSK3BHPGD | |
| SCHEMBL18109838 | 0.76 | HSF1 (0.53) | HSF1PIRBRAFGSK3BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2024-08-01 | — | — | US | claimed |
| EP-3521286-B1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2021-09-29 | — | — | EP | claimed |
| US-11124501-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-09-21 | — | — | US | claimed |
| EP-3521286-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | Cancer Research Technology Ltd. (GB) | 2019-08-07 | — | — | EP | claimed |
| US-20190106413-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-11 | — | — | US | claimed |
| EP-3052492-B1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2019-03-27 | — | — | EP | claimed |
| US-10189821-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-29 | — | — | US | claimed |
| US-20170037036-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-02-09 | — | — | US | claimed |
| US-20160289216-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-06 | — | — | US | claimed |
| EP-3052492-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | Cancer Research Technology Limited (GB) | 2016-08-10 | — | — | EP | claimed |
| WO-2015049535-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-09 | — | — | WO | claimed |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2024-08-01 | — | — | US | disclosed |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20220220097-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-07-14 | — | — | US | disclosed |
| EP-3521286-B1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-9701664-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-20170037036-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| US-20160289216-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-06 | — | — | US | disclosed |
| EP-3052492-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | Cancer Research Technology Limited (GB) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049535-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106413-A1 | INHIBITOR COMPOUNDS | HSF1, HSP90AB1, HSP90AA1 | HSF1 1/4885PIR 3555/4885BRAF 307/4885 |
| US-10189821-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | HSF1, HSP90AB1, HSPB1 | HSF1 1/4885PIR 3676/4885BRAF 1660/4885 |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | HSF1 1/4885PIR 3795/4885BRAF 1518/4885 |
| US-20170037036-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I | HSF1, HSP90AB1, HSPB1 | HSF1 1/4885PIR 3676/4885BRAF 1660/4885 |
| US-20160289216-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | HSF1 1/4885PIR 3817/4885BRAF 1509/4885 |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | HSF1, HSP90AB1, HSPB1 | HSF1 1/4885PIR 3795/4885BRAF 1518/4885 |
| US-20220220097-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | HSF1 1/4885PIR 3795/4885BRAF 1518/4885 |
| US-11124501-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | HSF1, HSP90AB1, HSPB1 | HSF1 1/4885PIR 3676/4885BRAF 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.